AIMS: BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1. We performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and pharmacokinetics of BI 2536 in five solid tumour types. PATIENTS AND METHODS: Patients with advanced head and neck, breast and ovarian cancer, soft tissue sarcoma and melanoma were selected according to protocol-defined general and tumour-specific criteria. They were 18years old, had a good performance status, adequate bone marrow, renal and liver function, measurable progressive disease and had completed other relevant systemic treatments >4weeks ago. BI 2536 200-250mg was given intravenously on day 1 every 3 weeks until intolerance, progression or refusal. The study was based on a Simon two-stage design, with 12 patients entering in stage 1 and additional 25 patients to be entered in case of at least one response in the first stage. The rate of objective responses (RECIST criteria) was chosen as primary end-point. RESULTS: Seventy six patients were included, 71 started treatment and received a median number of two cycles (four in ovarian cancer). Frequent grade 3-4 adverse events were neutropaenia (81.6%), thrombocytopaenia (19.7%), febrile neutropaenia (19.7%), anaemia (15.5%) and pain (9.9%). We did not observe confirmed objective responses. All cohorts were closed after the entry of 14-15 eligible non-responding patients. Pharmacokinetic analyses revealed multi-compartmental behaviour and a rapid distribution of BI 2536. CONCLUSIONS: BI 2536 showed limited antitumour activity according to the design of this trial in five different tumour types. Derivatives of BI 2536 with a more favourable pharmacological profile are currently explored further in prospective studies. Copyright 2010 Elsevier Ltd. All rights reserved.
AIMS: BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1. We performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and pharmacokinetics of BI 2536 in five solid tumour types. PATIENTS AND METHODS: Patients with advanced head and neck, breast and ovarian cancer, soft tissue sarcoma and melanoma were selected according to protocol-defined general and tumour-specific criteria. They were 18years old, had a good performance status, adequate bone marrow, renal and liver function, measurable progressive disease and had completed other relevant systemic treatments >4weeks ago. BI 2536 200-250mg was given intravenously on day 1 every 3 weeks until intolerance, progression or refusal. The study was based on a Simon two-stage design, with 12 patients entering in stage 1 and additional 25 patients to be entered in case of at least one response in the first stage. The rate of objective responses (RECIST criteria) was chosen as primary end-point. RESULTS: Seventy six patients were included, 71 started treatment and received a median number of two cycles (four in ovarian cancer). Frequent grade 3-4 adverse events were neutropaenia (81.6%), thrombocytopaenia (19.7%), febrile neutropaenia (19.7%), anaemia (15.5%) and pain (9.9%). We did not observe confirmed objective responses. All cohorts were closed after the entry of 14-15 eligible non-responding patients. Pharmacokinetic analyses revealed multi-compartmental behaviour and a rapid distribution of BI 2536. CONCLUSIONS:BI 2536 showed limited antitumour activity according to the design of this trial in five different tumour types. Derivatives of BI 2536 with a more favourable pharmacological profile are currently explored further in prospective studies. Copyright 2010 Elsevier Ltd. All rights reserved.
Authors: Christopher J Logothetis; Gary E Gallick; Sankar N Maity; Jeri Kim; Ana Aparicio; Eleni Efstathiou; Sue-Hwa Lin Journal: Cancer Discov Date: 2013-06-28 Impact factor: 39.397
Authors: Jens Wagenblast; Daniel Hirth; Laura Thron; Christoph Arnoldner; Marc Diensthuber; Timo Stöver; Markus Hambek Journal: Oncol Lett Date: 2012-04-30 Impact factor: 2.967
Authors: Jörg Haupenthal; Verena Bihrer; Huedayi Korkusuz; Otto Kollmar; Christian Schmithals; Susanne Kriener; Knut Engels; Thomas Pleli; Alexander Benz; Marta Canamero; Thomas Longerich; Bernd Kronenberger; Swantje Richter; Oliver Waidmann; Thomas J Vogl; Stefan Zeuzem; Albrecht Piiper Journal: Neoplasia Date: 2012-05 Impact factor: 5.715
Authors: Michel D Wissing; Janet Mendonca; Madeleine S Q Kortenhorst; Nadine S Kaelber; Matthew Gonzalez; Eunice Kim; Hans Hammers; Paul J van Diest; Michael A Carducci; Sushant K Kachhap Journal: FASEB J Date: 2013-07-24 Impact factor: 5.191
Authors: Martin Leinung; Daniel Hirth; Aykut Tahtali; Marc Diensthuber; Timo Stöver; Jens Wagenblast Journal: Oncol Lett Date: 2012-09-20 Impact factor: 2.967
Authors: Renata Ferrarotto; Ruchitha Goonatilake; Suk Young Yoo; Pan Tong; Uma Giri; Shaohua Peng; John Minna; Luc Girard; Yuehong Wang; Liguang Wang; Lerong Li; Lixia Diao; David H Peng; Don L Gibbons; Bonnie S Glisson; John V Heymach; Jing Wang; Lauren A Byers; Faye M Johnson Journal: Clin Cancer Res Date: 2015-11-23 Impact factor: 12.531